XENICAL GAINS EU APPROVAL FOR USE IN YOUNG PEOPLE

Roche has announced that its leading weight loss medicine Xenical (orlistat) has received European approval to include clinical, safety and efficacy data in the label on the use in obese adolescents aged 12 years or over. The label change has been approved following the results of a major study that shows Xenical to be highly effective in helping obese young people to lose weight. As a result of this change, physicians may now consider Xenical as an effective option in the management of obesity in adolescents.

PharmaLive (http://www.medadnews.com/News/index.cfm?articleid=252130)